Document Detail

Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
MedLine Citation:
PMID:  16412929     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To determine the penetration of moxifloxacin 0.5% in the human aqueous and vitreous when delivered by a presoaked collagen shield. SETTING: University-based clinical practice. METHODS: Moxifloxacin 0.5% was administered before vitrectomy surgery in 10 patients using a 24-hour dissolvable cross-linked corneal collagen shield delivery device. Aqueous and vitreous samples were obtained after the shield was placed for 4 hours in the first 5 patients and for 24 hours in the second 5 patients. Assays were performed using high-performance liquid chromatography. RESULTS: Delivery of moxifloxacin via a collagen shield revealed a mean aqueous concentration of 0.30 microg/mL +/- 0.17 (SD) 4 hours after placement (n = 5). Vitreous levels at 4 hours and aqueous and vitreous levels at 24 hours were negligible using this route of administration. Peak aqueous moxifloxacin levels occurred soon after shield placement. This is when high concentrations of moxifloxacin are most needed to clear the aqueous of bacteria. The minimum inhibitory concentration at which 90% of the isolates were inhibited for organisms commonly responsible for endophthalmitis was exceeded in the 4-hour aqueous group. Negligible concentrations were detected at 24 hours. CONCLUSIONS: Although aqueous moxifloxacin levels achieved through the use of a collagen shield delivery device are lower than via topical drops, there are several advantages to this route of delivery that make it appealing in the immediate postoperative period. Future studies will be needed to define precisely the role of fourth-generation fluoroquinolones and presoaked collagen shields in the prophylaxis or management of intraocular infections.
Seenu M Hariprasad; Gaurav K Shah; Jingduan Chi; Randall A Prince
Related Documents :
16044319 - Structural and mechanical architecture of the intestinal villi and crypts in the rat in...
9219679 - The effect of strenuous versus moderate exercise on the metabolism of proteoglycans in ...
8877929 - Coordinated regulation of hyaluronan and aggrecan content in the articular cartilage of...
16849829 - Adaptation of the tendon to mechanical usage.
18266999 - Noninvasive measures of blood volume and oxygen saturation of human achilles tendon by ...
22569039 - Exercise-induced muscle damage is reduced in resistance-trained males by branched chain...
20086399 - Chronic fatigue syndrome: matching exercise to symptom fluctuations.
1629079 - Dynamics of ventilation, circulation, and gas exchange to incremental and decremental r...
21034539 - Heart rate profile during exercise in patients with early repolarization.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cataract and refractive surgery     Volume:  31     ISSN:  0886-3350     ISO Abbreviation:  J Cataract Refract Surg     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2006-01-17     Completed Date:  2006-03-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8604171     Medline TA:  J Cataract Refract Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2142-6     Citation Subset:  IM    
Department of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Bacterial Agents / administration & dosage,  pharmacokinetics*
Aqueous Humor / metabolism*
Aza Compounds / administration & dosage,  pharmacokinetics*
Biodegradation, Environmental
Biological Availability
Chromatography, High Pressure Liquid
Cornea / metabolism*
Drug Carriers*
Drug Delivery Systems
Microbial Sensitivity Tests
Middle Aged
Ophthalmic Solutions / administration & dosage,  pharmacokinetics
Quinolines / administration & dosage,  pharmacokinetics*
Vitreous Body / metabolism*
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Aza Compounds; 0/Drug Carriers; 0/Ophthalmic Solutions; 0/Quinolines; 0/moxifloxacin; 9007-34-5/Collagen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium f...
Next Document:  Phacofragmentation with perfluorocarbon liquid and anterior chamber or scleral-fixated intraocular l...